Good News for InterMune - Analyst Blog

By
A A A

InterMune, Inc. ( ITMN ) recently received encouraging news when the pricing and reimbursement conditions for its sole marketed drug, Esbriet, were approved by the Board of the Italian Drug Agency (AIFA). Esbriet is approved in the EU for the treatment of idiopathic pulmonary fibrosis (IPF), a fatal lung disease.

InterMune mentioned in its press release that around 6,000 to 9,000 patients suffering from mild-to-moderate IPF are currently living in Italy. Once launched, Esbriet will be the first drug to be commercially available in Italy for the treatment of IPF. InterMune expects the reimbursement process of the drug to start within the next few days. Esbriet's gross ex-factory price is set at around $44,000 per patient, per year and is subject to a mandatory national discount of 9.75%.

Meanwhile, Esbriet has been successfully priced and reimbursed in 11 other European countries apart from Italy, namely, Austria, Belgium, Denmark, France, Germany, Iceland, Luxembourg, Norway, Sweden, England, and Finland. The drug is already launched in all these countries except England and Finland where it will be launched soon. InterMune believes that it will generate revenues from these countries from the second half of this year.

Moreover, InterMune plans to conclude pricing and reimbursement discussions in Ireland shortly and potentially launch the drug there in the third quarter of 2013. The company also expects to provide an update on pricing and reimbursement discussions in Spain and the Netherlands by the end of the year.

InterMune expects to generate around $40−$70 million of Esbriet sales in 2013. The guidance includes $40-$55 million from countries where the product is currently launched and the rest from countries where the drug is yet to be launched.

Though Esbriet is the only approved medicine for IPF, companies like Novartis ( NVS ) and Sanofi ( SNY ) are also developing candidates for IPF.

InterMune presently carries a Zacks Rank #3 (Hold). However, biotech stock Elan Corporation, plc ( ELN ) currently looks more attractive with a Zacks Rank #2 (Buy).



ELAN CP PLC ADR (ELN): Free Stock Analysis Report

INTERMUNE INC (ITMN): Free Stock Analysis Report

NOVARTIS AG-ADR (NVS): Free Stock Analysis Report

SANOFI-AVENTIS (SNY): Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research



The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of The NASDAQ OMX Group, Inc.



This article appears in: Investing , Business , Stocks

Referenced Stocks: ELN , IPF , ITMN , NVS , SNY

Zacks.com

Zacks.com

More from Zacks.com:

Related Videos

Stocks

Referenced

Most Active by Volume

61,354,178
  • $10.59 ▲ 13.26%
57,732,182
  • $16.27 ▲ 1.12%
51,991,548
  • $103.30 ▲ 0.78%
48,129,834
  • $20.65 ▲ 5.52%
41,623,916
  • $12.63 ▲ 8.13%
34,295,241
  • $76.68 ▲ 2.49%
31,519,079
  • $34.57 ▼ 1.00%
28,847,879
  • $3.64 ▲ 0.28%
As of 9/2/2014, 04:15 PM

Find a Credit Card

Select a credit card product by:
Select an offer:
Search
Data Provided by BankRate.com